Business Context and Reporting Period
Company: HAPC, Inc. (formerly Healthcare Acquisition Partners Corp.)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2006
Status: Development stage "blank check" company (Special Purpose Acquisition Company or SPAC) incorporated in Delaware on August 15, 2005. The company's objective is to acquire one or more operating businesses primarily in the healthcare sector.
Key Financial Metrics
| Metric | Value (as of June 30, 2006) |
|---|---|
| Cash and Cash Equivalents | $97,874,951 |
| Total Assets | $98,548,200 |
| Total Liabilities | $5,603,749 |
| Stockholders' Equity | $92,944,451 |
| Revenues | $0 (No operating revenue) |
| Net Loss (Six Months Ended June 30, 2006) | $(3,895,842) |
| Net Loss (Three Months Ended June 30, 2006) | $(1,697,121) |
| Interest Income | $857,032 (Six Months) |
| Deferred Underwriting Fees | $5,400,000 (Liability) |
| Trust Account Balance | Approx. $96,215,000 (Held in trust) |
Material Changes vs. Prior Period
- Initial Public Offering (IPO): The company consummated its IPO on April 18, 2006, selling 16,666,667 units at $6.00 per unit. On May 18, 2006, an additional 208,584 units were sold via partial exercise of the overallotment option. Total gross proceeds were approximately $101.25 million.
- Liquidity Surge: Cash increased from $13,590 as of December 31, 2005, to $97,874,951 as of June 30, 2006, driven entirely by IPO proceeds.
- Asset Growth: Total assets grew from $178,678 to $98,548,200.
- Liabilities: Total liabilities increased to $5.6 million, primarily due to the recording of $5.4 million in deferred underwriting fees payable upon the consummation of a business combination.
- Stockholder Equity: Equity shifted from a deficit of $(376) to $92.9 million following the capital raise.
Guidance, Outlook, and Risks
Outlook and Strategy: The company intends to use substantially all net proceeds (approx. $98 million) to acquire a target business with a fair market value of at least 80% of net assets. Approximately $96.2 million is held in a Trust Account invested in U.S. government securities. The company has 18 months (extendable to 24 months) to consummate a business combination; otherwise, it must liquidate.
Management Commentary: Management notes that operating results for the interim period are not indicative of future results. The net loss is primarily driven by non-cash stock-based compensation expenses and general administrative costs related to the IPO and search for a target.
Risks and Contingencies:
- Liquidation Risk: If a business combination is not completed within the timeframe, the company will liquidate. Public stockholders may receive less than $6.00 per share due to expenses and taxes.
- Subsequent Event (Stock Compensation): On July 24, 2006, the company reserved 2,416,666 shares for directors. This will result in a charge of approximately $13.05 million in the quarter ended September 30, 2006.
- Regulatory and Industry Risks: As a healthcare-focused SPAC, the company faces risks related to government regulation (FDA, Medicare/Medicaid), liability exposure, and industry consolidation.
- Conflicts of Interest: Officers and directors have other business affiliations and may have conflicts regarding the allocation of time and presentation of business opportunities.
Investor Verification Checklist
- Trust Account Status: Verify the exact balance and interest earnings in the Trust Account, as this determines the liquidation value if no deal is found.
- Deferred Underwriting Fee: Confirm the $5.4 million deferred fee obligation and the conditions under which it is payable or forfeited.
- Upcoming Expenses: Review the impact of the $13.05 million stock-based compensation charge disclosed as a subsequent event for the Q3 2006 period.
- Warrant Terms: Understand the redemption terms of the 33.75 million warrants issued (exercise price $5.00, redemption price $0.01 if stock price exceeds $8.50).
- Extension Criteria: Review the specific criteria required to extend the 18-month deadline to 24 months.